Skip to content

Photobiomodulation and Parkinson

Photobiomodulation in Parkinson´s Disease: A Randomized Controlled Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03811613
Enrollment
35
Registered
2019-01-22
Start date
2018-01-29
Completion date
2018-03-30
Last updated
2025-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

movement disorders, light therapy, motor aspects

Brief summary

This study aimed to assess the effects of transcranial photobiomodulation in patients with Parkinson's disease (PD).

Detailed description

Thirty-five patients with idiopathic PD were randomly assigned to a photobiomodulation (n=17, \[mean±SD\] 72±7 years) or sham group (n=18, 70±8 years) during 9 weeks (2 sessions/week). The primary endpoint was the motor portion of the Movement Disorders Society-United PD Rating Scale. Secondary endpoints were the Scales for Outcomes in PD, static posturography, walking ability (ten-meter walk test \[TMWT\]) and functional mobility (timed up and go \[TUG\] test).

Interventions

Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)

Sponsors

University of Oviedo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Having been diagnosed with idiopathic PD. * Stage 1-2 on the Hoehn and Yahr Scale. * Having no neurological condition other than PD. * Being able to stand for 2 minutes and walk 10 meters without assistance. * Having no severe dyskinesias or ON-OFF phases.

Exclusion criteria

\- Do not follow inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
The motor portion of the MDS-UPDRS.9 weeksThe motor portion (part III) Movement Disorders Society-Unified PD Rating Scale. It assesses the motor signs of Parkinson´s disease (minimum and maximum score is 0 and 76 points respectively -the higher score, the higher movement disorder and vice versa-).

Secondary

MeasureTime frameDescription
Motor function9 weeksThe Spanish-validated version of the Short Parkinson's Evaluation Scale (SPES)/Scales for Outcomes in PD (SCOPA). It measures the Parkinson´s disease patients motor function (minimum and maximum score is 0 and 63 points respectively -the higher score, the worse motor function and vice versa-).
Static posturography9 weeksThe centre of pressure (CoP) parameters (these CoP parameters; Length in mm, Area in mm2 and Speed in m/s are combined to report the static posturography).
Walking speed9 weeksTen-meter walk test
TUG9 weeksTimed up and go test

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026